Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].
When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors? / Marasco, Matteo; Galasso, Domenico; Larghi, Alberto; Panzuto, Francesco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:14(2023), pp. 1-4. [10.3390/jcm12144581]
When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
Marasco, Matteo;Panzuto, Francesco
2023
Abstract
Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Marasco_When-Should-We-Adopt-EUS-Guided-Radiofrequency_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
213.98 kB
Formato
Adobe PDF
|
213.98 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
